Abeona Therapeutics acquires ABO-801 from Ellodi Pharma for $20M equity, raises $30M private placement

Abeona Therapeutics is acquiring ABO-801, a product candidate for eosinophilic esophagitis, from Ellodi Pharma for $20M in equity consideration, and entered a securities purchase agreement for a $30M private placement financing.

Detected & updated continuously · Source: Nebula